Lifecore Biomedical (LFCR) Expected to Post Quarterly Earnings on Tuesday

Lifecore Biomedical (NASDAQ:LFCR) is anticipated to issue its Q3 2026 resultson Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.2975) per share and revenue of $25.57 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Wednesday, August 5th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $34.17 million for the quarter, compared to analysts’ expectations of $34.18 million. On average, analysts expect Lifecore Biomedical to post ($1.02) EPS for the current fiscal year and ($1.08) EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of LFCR opened at $6.44 on Tuesday. Lifecore Biomedical has a 1-year low of $3.63 and a 1-year high of $8.98. The stock has a market cap of $243.75 million, a PE ratio of -6.02 and a beta of 0.98. The firm has a 50-day simple moving average of $5.26 and a two-hundred day simple moving average of $5.56.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. William Blair lowered shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a report on Monday, September 28th. Craig Hallum cut shares of Lifecore Biomedical from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Weiss Ratings upgraded shares of Lifecore Biomedical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Barrington Research lowered Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research report on Tuesday, September 29th. Finally, Zacks Research raised Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $6.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a contract development and manufacturing organization that provides development, formulation, aseptic filling, packaging and other manufacturing services for pharmaceutical and biopharmaceutical companies. The company specializes in complex sterile injectable products and supports customers from development through commercial production.

Lifecore has particular expertise in hyaluronic acid, a naturally occurring substance used in ophthalmic, orthopedic, aesthetic and other medical applications.